News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中生製藥(01177.HK)TQB6411臨床研究顯示有效劑量下呈現良好安全性特徵
中國生物製藥(01177.HK)公布，其附屬正大天晴自主研發的國家1類創新藥TQB6411「EGFR/c-Met ADC」於2026年美國臨床腫瘤學會(ASCO)大會上公布在晚期實體瘤患者中的首次人體I期臨床研究數據。研究表明，TQB6411在有效劑量下呈現良好的安全性特徵，尤其是血液學毒性較低。TQB6411對c-Met端的親和力強於EGFR端(效價比為1...
Reset
Send
The window will close in 5 seconds
中生製藥(01177.HK)TQB6411臨床研究顯示有效劑量下呈現良好安全性特徵
Close
Recommend
14
Positive
19
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

中國生物製藥(01177.HK)  -0.130 (-2.725%)    Short selling $48.58M; Ratio 21.424%   公布，其附屬正大天晴自主研發的國家1類創新藥TQB6411「EGFR/c-Met ADC」於2026年美國臨床腫瘤學會(ASCO)大會上公布在晚期實體瘤患者中的首次人體I期臨床研究數據。

研究表明，TQB6411在有效劑量下呈現良好的安全性特徵，尤其是血液學毒性較低。TQB6411對c-Met端的親和力強於EGFR端(效價比為1:2)，該特徵一方面增強對c-Met高表達腫瘤細胞的殺傷作用，另一方面有助於減少靶向EGFR帶來的皮膚毒性等不良反應。在抗腫瘤藥物肺毒性方面，本研究過程中未發生間質性肺病(ILD)。(jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-04 12:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.